Presentation - Roche

Roche Pharma Research & Early Development (pRED) Accessing external innovation Michael Schröter – Nov 2012

2

Transforming deals and external innovation into medicines

Partner agreement In-licensed *2011 sales figures

CHF m CHF m

Mabthera/Rituxan 6,005 Actemra/RoActemra 618

Avastin 5,292 Xolair 603

Herceptin 5,253 Valcyte/Cymevene 569

Lucentis 1,523 Pulmozyme 492

Pegasys 1,438 Activase/TNKase 453

Xeloda 1,354 Tamiflu 359

Tarceva 1,251 Mircera 344

CellCept 991 Nutropin 317

NeoRec/Epogin 896 Madopar 294

Bonviva/Boniva 696 Neutrogin 278

CHF m CHF m

Mabthera/Rituxan 6,005 Actemra/RoActemra 618

Avastin 5,292 Xolair 603

Herceptin 5,253 Valcyte/Cymevene 569

Lucentis 1,523 Pulmozyme 492

Pegasys 1,438 Activase/TNKase 453

Xeloda 1,354 Tamiflu 359

Tarceva 1,251 Mircera 344

CellCept 991 Nutropin 317

NeoRec/Epogin 896 Madopar 294

Bonviva/Boniva 696 Neutrogin 278

3

Global Access to Talent Diversity

pRED Strategy – How We Win Translating science into medical innovation for patients

3

Scientific opportunity and medical need

Translational Medicine Expertise

Leading Technology Platforms

External R&D

Innovation Network

Our key capabilities to deliver a diverse and high value portfolio

Exploratory Areas

Excel in our Focus Areas

Neuroscience Oncology

CV & Metabolism Virology

Our focus Three pillars to execute our strategy

pRED research and translational medicine hubs A new mode for collaboration with academia

4

Pre-clinical Development

Clinical Development

Pharma

• new targets / new molecules • cuttting edge pathway & biology

research

• selected patient populations • cutting edge technologies (e.g.

imaging

Research Clinic Partner (universities, institutes, etc.)

Translational R&D Hub

Establish, manage and lead a strong networks of academic partnerships to deliver on pRED projects and to enhance the pRED portfolio

5

Technology partnerships

Singapore • Network of 26 academic partner institutes,

several programs, e.g. angiogenesis • SERI – R&D partnership in Ophthalmology • Virtual R&D unit with financial reimbursements

Netherlands Imaging Hub • Collaborative Hub of 3 world-class academic

imaging sites

French R&D Institute • Access to academic innovation

network with positive impact on key European affiliate

Montreal Heart Institute • Cardiovascular center of excellence

Swiss University Network • Basel, neuroscience cognition research

and ETH Zurich, joint Rx / Dx hub

pRED External Innovation Network Complementing our capabilities and amplifying our ability to innovate

Harvard • iPSC (stem cells)

PTC Therapeutics • Advanced treatment options for

spinal muscular atrophy

Baylor • Therapeutic vaccines

Geneva University • Proteomics and

pathway analysis

Yissum • Novel pathways, β-cell stem

cells discovery, CV risk biomarkers

Mt Sinai • Novel screening approaches

in Virology

Technology partnerships Translational hubs

6

Roche Institute for Research & Translational Medicine A new R&D structure dedicated to partnerships

• 48 partnerships with Academic Centers • pRED team based in France : Academic Alliance

scientists dedicated to local collaborative R&D projects

• 6 Roche Employees + 11 PhD or post-docs

Nanotechnologies Biomarkers

Key features of value for DTAs/ Functions

7

Dutch Imaging Network Allowing pRED to access leading imaging capabilities in Europe

• World class for imaging antibody distribution

• Excellent clinical and pre-clinical imaging facilities and expertise

• A novel mode of working together: close scientific collaboration

• Excellence in imaging for oncology, neuroscience and inflammation

Nijmegen

Amsterdam

Creating a strategic alliance with Key features of value for DTAs/ Functions

Through the Dutch hub we are able to ‘do more, with less’ by leveraging external capabilities rather than utilizing our own expenditure to build up our own capabilities

Groningen

8

Diagnostic development

Drug development

Evaluation of biomarkers vs. clinical response

Phase III

Companion Diagnostic Development GLP Biomarker Assay Development

Replication Discovery & hypothesis generation

Launch with Companion Diagnostic

Phase I Phase III Early Development Research Phase II

Personalised healthcare as a key enabler Innovation across the value chain

9 9

We Innovate Healthcare

10

Roche Group – structure

Pharmaceuticals Diagnostics